Sanofi to Post Q2 2024 Earnings of $0.90 Per Share, Leerink Partnrs Forecasts (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Equities researchers at Leerink Partnrs lowered their Q2 2024 earnings estimates for shares of Sanofi in a report issued on Thursday, April 25th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of $0.90 for the quarter, down from their previous forecast of $0.91. The consensus estimate for Sanofi’s current full-year earnings is $4.09 per share. Leerink Partnrs also issued estimates for Sanofi’s Q4 2024 earnings at $0.87 EPS, FY2026 earnings at $4.95 EPS and FY2027 earnings at $5.47 EPS.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%.

Other analysts also recently issued reports about the stock. Morgan Stanley began coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target on the stock. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Finally, TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $55.00.

Sanofi Stock Down 0.5 %

SNY stock opened at $49.13 on Monday. Sanofi has a 52 week low of $42.63 and a 52 week high of $56.26. The company has a market capitalization of $124.28 billion, a price-to-earnings ratio of 24.69, a price-to-earnings-growth ratio of 1.48 and a beta of 0.61. The firm’s 50-day moving average is $47.71 and its two-hundred day moving average is $48.32. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

Institutional Trading of Sanofi

Hedge funds have recently bought and sold shares of the stock. Clearbridge Investments LLC lifted its holdings in shares of Sanofi by 8.4% during the 3rd quarter. Clearbridge Investments LLC now owns 184,630 shares of the company’s stock worth $9,904,000 after acquiring an additional 14,362 shares during the period. Dynamic Advisor Solutions LLC bought a new position in Sanofi during the 4th quarter worth approximately $2,104,000. Soros Fund Management LLC bought a new position in Sanofi during the 3rd quarter worth approximately $11,533,000. International Assets Investment Management LLC bought a new position in Sanofi during the 4th quarter worth approximately $4,704,000. Finally, Clear Street Markets LLC lifted its stake in Sanofi by 352.8% in the third quarter. Clear Street Markets LLC now owns 130,183 shares of the company’s stock valued at $6,983,000 after buying an additional 101,430 shares in the last quarter. 10.04% of the stock is owned by institutional investors.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a dividend of $1.478 per share. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio is currently 69.35%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.